Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma

This study has been withdrawn prior to enrollment.
(Funding was removed.)
Sponsor:
Collaborators:
GlaxoSmithKline
Gilead Sciences
Information provided by (Responsible Party):
University of Michigan Cancer Center
ClinicalTrials.gov Identifier:
NCT01528865
First received: January 12, 2012
Last updated: March 10, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)